The estimated Net Worth of Y. Paul Goldberg is at least $1.09 Millón dollars as of 22 September 2015. Y Goldberg owns over 30,388 units of Xenon Pharmaceuticals Inc stock worth over $1,094,413 and over the last 10 years Y sold XENE stock worth over $0.
Sign up
Y Goldberg XENE stock SEC Form 4 insiders trading
Y has made over 2 trades of the Xenon Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Y exercised 30,388 units of XENE stock worth $98,457 on 22 September 2015.
The largest trade Y's ever made was exercising 30,388 units of Xenon Pharmaceuticals Inc stock on 22 September 2015 worth over $98,457. On average, Y trades about 4,184 units every 4 days since 2015. As of 22 September 2015 Y still owns at least 28,316 units of Xenon Pharmaceuticals Inc stock.
You can see the complete history of Y Goldberg stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Y Goldberg's mailing address?
Y's mailing address filed with the SEC is C/O XENON PHARMACEUTICALS INC, 200 - 3650 GILMORE WAY, BURNABY, A1, V5G 4W8.
Insiders trading at Xenon Pharmaceuticals Inc
Over the last 10 years, insiders at Xenon Pharmaceuticals Inc have traded over $12,977,011 worth of Xenon Pharmaceuticals Inc stock and bought 724,015 units worth $2,649,316 . The most active insiders traders include Patrick Machado, Partners L P/Ilbiotechnolog... y Justin D. Gover. On average, Xenon Pharmaceuticals Inc executives and independent directors trade stock every 31 days with the average trade being worth of $818,878. The most recent stock trade was executed by Elizabeth A. Garofalo on 8 March 2024, trading 3,500 units of XENE stock currently worth $64,960.
What does Xenon Pharmaceuticals Inc do?
xenon® (nasdaq: xene) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as extreme genetics. our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits, or phenotypes. we apply our expertise to predict which phenotypes are caused by single-gene defects. by identifying and characterizing the single-gene defects responsible for such severe phenotypes, we gain valuable insights into their function in human biology and their potential as drug targets. given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, we are developing proprietary product candidates to treat both orphan as well as more prevalent diseases.
What does Xenon Pharmaceuticals Inc's logo look like?
Complete history of Y Goldberg stock trades at Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc executives and stock owners
Xenon Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Simon Pimstone,
Chief Executive Officer, Director -
Ian Mortimer,
President, Chief Financial Officer, Corporate Secretary -
Ernesto Aycardi-Fonseca,
Chief Medical Officer -
Dr. Simon N. Pimstone FRCPC, M.B. ChB., M.D., Ph.D.,
Exec. Chairman -
Ian C. Mortimer C.M.A., CPA, CMA, CPA, M.B.A., MBA,
Pres, CEO & Director -
Robin Sherrington,
Executive Vice President - Strategy & Innovation -
James Empfield,
Senior Vice President - Drug Discovery -
Dr. Christopher John Kenney M.D.,
Chief Medical Officer -
Michael Tarnow,
Independent Chairman of the Board -
Dawn Svoronos,
Independent Director -
Gary Patou,
Independent Director -
Frank Holler,
Independent Director -
Michael Hayden,
Independent Director -
Steven Gannon,
Independent Director -
Clarissa Desjardins,
Independent Director -
Mohammad Azab,
Independent Director -
Shelley McCloskey,
Senior Vice President - Human Resources -
Dr. Christopher E. Von Seggern M.B.A., M.P.H., M.P.H. M.B.A, Ph.D.,
Chief Commercial Officer -
Dr. Kenneth Sommerville,
Interim Chief Medical Officer -
Dr. Christopher E. Von Seggern M.B.A., M.P.H., Ph.D., M.P.H. M.B.A,
Chief Commercial Officer -
Sheila M. Grant M.B.A., M.Sc., MBA,
Sr. VP of R&D Operations -
Dr. James R. Empfield,
Exec. VP of Drug Discovery -
Dr. Robin P. Sherrington,
Exec. VP of Strategy & Innovation -
Shelley McCloskey B.A.,
Sr. VP of HR -
Jodi Regts M.B.A., B.A., MBA,
VP of Corp. Affairs & Investor Relations -
Sherry Aulin,
Chief Financial Officer -
Charles J. Cohen,
VP, Biology -
Raymond Winquist,
Head, Translational Research -
Partners L P/Ilbiotechnolog...,
-
Richard H Scheller,
Director -
Christopher John Kenney,
Chief Medical Officer -
Sherry Aulin,
Chief Financial Officer -
Seggern Christopher Von,
Chief Commercial Officer -
Elizabeth A. Garofalo,
-
Patrick Machado,
-
Y. Paul Goldberg,
VP, Clinical Development -
Associates, Llp Mx,
10% owner -
Karen G. Corraini,
Gen. Counsel & Corp. Secretary -
Johnston L Evans,
Director -
Evan A. Stein,
Director -
Gary Bridger,
EVP, Research & Development -
Gillian Cannon,
-
Justin D. Gover,